204 related articles for article (PubMed ID: 38216951)
1. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance.
Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK
J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951
[TBL] [Abstract][Full Text] [Related]
2. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.
Asare-Werehene M; Nakka K; Reunov A; Chiu CT; Lee WT; Abedini MR; Wang PW; Shieh DB; Dilworth FJ; Carmona E; Le T; Mes-Masson AM; Burger D; Tsang BK
Oncogene; 2020 Feb; 39(7):1600-1616. PubMed ID: 31700155
[TBL] [Abstract][Full Text] [Related]
3. Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes.
Asare-Werehene M; Tsuyoshi H; Zhang H; Salehi R; Chang CY; Carmona E; Librach CL; Mes-Masson AM; Chang CC; Burger D; Yoshida Y; Tsang BK
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205790
[TBL] [Abstract][Full Text] [Related]
4. Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance.
Onuma T; Asare-Werehene M; Yoshida Y; Tsang BK
Cells; 2022 Oct; 11(20):. PubMed ID: 36291171
[TBL] [Abstract][Full Text] [Related]
5. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.
Gerber E; Asare-Werehene M; Reunov A; Burger D; Le T; Carmona E; Mes-Masson AM; Tsang BK
J Ovarian Res; 2023 Jan; 16(1):14. PubMed ID: 36642715
[TBL] [Abstract][Full Text] [Related]
6. Plasma Gelsolin Inhibits CD8
Asare-Werehene M; Communal L; Carmona E; Han Y; Song YS; Burger D; Mes-Masson AM; Tsang BK
Cancer Res; 2020 Sep; 80(18):3959-3971. PubMed ID: 32641415
[TBL] [Abstract][Full Text] [Related]
7. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.
Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X
Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance.
Sung HY; Han J; Chae YJ; Ju W; Lee Kang J; Park AK; Ahn JH
BMB Rep; 2023 Jun; 56(6):347-352. PubMed ID: 37013346
[TBL] [Abstract][Full Text] [Related]
9. Effect of TET1 regulating MGMT on chemotherapy resistance of oral squamous cell carcinoma stem cells.
Wang W; Li X; Wang F; Sun XY
J Cell Biochem; 2018 Jan; 119(1):723-735. PubMed ID: 28643947
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
11. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
[TBL] [Abstract][Full Text] [Related]
12. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
[TBL] [Abstract][Full Text] [Related]
13. The Application of an Extracellular Vesicle-Based Biosensor in Early Diagnosis and Prediction of Chemoresponsiveness in Ovarian Cancer.
Asare-Werehene M; Hunter RA; Gerber E; Reunov A; Brine I; Chang CY; Chang CC; Shieh DB; Burger D; Anis H; Tsang BK
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174032
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
[TBL] [Abstract][Full Text] [Related]
15. Cell fate regulation by gelsolin in human gynecologic cancers.
Abedini MR; Wang PW; Huang YF; Cao M; Chou CY; Shieh DB; Tsang BK
Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14442-7. PubMed ID: 25246592
[TBL] [Abstract][Full Text] [Related]
16. miR-29c-3p acts as a tumor promoter by regulating β-catenin signaling through suppressing DNMT3A, TET1 and HBP1 in ovarian carcinoma.
Zhao H; Feng L; Cheng R; Wu M; Bai X; Fan L; Liu Y
Cell Signal; 2024 Jan; 113():110936. PubMed ID: 37925048
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.
Asare-Werehene M; Communal L; Carmona E; Le T; Provencher D; Mes-Masson AM; Tsang BK
Sci Rep; 2019 Sep; 9(1):13924. PubMed ID: 31558772
[TBL] [Abstract][Full Text] [Related]
18. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
20. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
Woo MG; Xue K; Liu J; McBride H; Tsang BK
J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
